Sponsor Check › Person
Related person on Form D filings · address states as listed: CA, NJ, MD, MA, WA · listed Nov 22, 2013 → Jan 5, 2017
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
7 of 32 offerings report sales commissions totalling $7,872,044; 0 report finder's fees; 2 report proceeds to related persons totalling $1,666,388. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Jan 2, 2018 D File 021-302145 | $3,630,000 (est.) | $0 | $0 | Maxim Group LLC BrokerCheck CRD 120708 ↗ Leerink Partners LLC BrokerCheck CRD 39011 ↗ |
| EDGAR ↗ | Dec 29, 2017 D File 021-301945 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 23, 2017 D File 021-287301 | $212,450 | $0 | $0 | Brookline Capital Markets no CRD number reported via CIM Securities, LLC (CRD 120852 ↗) |
| EDGAR ↗ | Mar 2, 2017 D File 021-281658 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 5, 2017 D File 021-277676 | $1,325,183 | $0 | $0 (est.) | N/A no CRD number reported via Maxim Group LLC (CRD 120708 ↗) |
| EDGAR ↗ | Dec 8, 2016 D File 021-275891 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 21, 2016 D File 021-265466 | $669,810 | $0 | $0 (est.) | N/A no CRD number reported via Maxim Group LLC (CRD 120708 ↗) |
| EDGAR ↗ | Apr 18, 2016 D File 021-261523 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 15, 2016 D File 021-261501 | $318,300 | $0 | $0 (est.) | N/A no CRD number reported via Maxim Group LLC (CRD 120708 ↗) |
| EDGAR ↗ | Mar 17, 2016 D/A File 021-229558 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 14, 2016 D File 021-259218 | $537,990 | $0 | $0 (est.) | N/A no CRD number reported via Maxim Group LLC (CRD 120708 ↗) |
| EDGAR ↗ | Mar 10, 2016 D File 021-258996 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 5, 2015 D File 021-231374 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 7, 2014 D File 021-216907 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 11, 2013 D/A File 021-179783 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 3, 2013 D/A File 021-206864 | $1,178,311 | $0 | $416,388 (est.) To pay back salary for executive officers: (1) Kerrie L. Brady, (2) James N. Campbell and (3) Jeffrey B. Kindler. | N/A no CRD number reported via Maxim Group LLC (CRD 120708 ↗) |
| EDGAR ↗ | Dec 3, 2013 D File 021-207282 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | May 23, 2013 D File 021-196991 | $0 | $0 | $0 The Issuer will use proceeds for general working capital purposes which includes payments to its executive officers and other employees in the ordinary course of business. | None listed on this filing |
| EDGAR ↗ | Apr 17, 2013 D/A File 021-52568 | $0 | $0 | $0 Proceeds from the offering will be used for general working capital. | None listed on this filing |
| EDGAR ↗ | Nov 29, 2012 D File 021-187610 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 1, 2012 D File 021-184847 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 18, 2012 D File 021-178492 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 3, 2012 D File 021-177663 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jun 21, 2011 D File 021-161614 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 31, 2011 D File 021-154617 | $0 | $0 | $0 The proceeds from the offering will be used for general working capital purposes. | None listed on this filing |
| EDGAR ↗ | Nov 1, 2010 D File 021-149834 | $0 | $0 | $0 The Issuer will use proceeds for general working capital purposes which includes payments to its executive officers and other employees in the ordinary course of business. | None listed on this filing |
| EDGAR ↗ | Apr 22, 2010 D File 021-140974 | $0 | $0 | $0 The Issuer will use proceeds for general working capital purposes which includes payments to its executive officers and other employees in the ordinary course of business. | None listed on this filing |
| EDGAR ↗ | Apr 5, 2010 D File 021-140181 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 22, 2010 D/A File 021-112966 | $0 | $0 | $0 The Issuer will use proceeds for general working capital purposes which includes payments to its executive officers and other employees in the ordinary course of business. | None listed on this filing |
| EDGAR ↗ | Feb 1, 2010 D File 021-112023 | $0 | $0 | $0 The Issuer will use proceeds for general working capital purposes which includes payments to its executive officers and other employees in the ordinary course of business. | None listed on this filing |
| EDGAR ↗ | Oct 2, 2009 D/A File 021-40517 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 16, 2009 D/A File 021-61188 | $0 | $0 | $1,250,000 (est.) | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Centrexion Therapeutics Corp | Director | Jan 2, 2018 | D | $69,566,532 similar: $2,000,000–$19,999,994 | $69,566,532 | 67 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Potenza Therapeutics, Inc. | Director | Dec 29, 2017 | D | $5,000,000 similar: $1,694,259–$16,000,000 | $5,000,000 | 5 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Centrexion Therapeutics Corp | Director | May 23, 2017 | D | Indefinite similar: $2,000,000–$19,999,994 | $5,285,000 | 40 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | PMV Pharmaceuticals, Inc. | Director | Mar 2, 2017 | D | $73,728,198 similar: $1,694,259–$16,000,000 | $73,728,198 | 9 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Centrexion Therapeutics Corp | Director | Jan 5, 2017 | D | $16,564,789 similar: $2,000,000–$19,999,994 | $16,564,789 | 14 similar: 2–16 | $25,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Integrated Diagnostics, Inc. | Director | Dec 8, 2016 | D | Indefinite similar: $2,000,000–$19,999,994 | $6,099,999 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Centrexion Therapeutics Corp | Director | Jun 21, 2016 | D | Indefinite similar: $2,000,000–$19,999,994 | $11,163,500 | 61 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | TESARO, Inc. | Director | Apr 18, 2016 | D | $49,999,960 similar: $1,694,259–$16,000,000 | $49,999,960 | 1 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Centrexion Therapeutics Corp | Director | Apr 15, 2016 | D | Indefinite similar: $2,000,000–$19,999,994 | $6,905,000 | 21 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Potenza Therapeutics, Inc. | Director | Mar 17, 2016 | D/A | $38,000,000 similar: $1,694,259–$16,000,000 | $30,000,000 | 6 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Centrexion Therapeutics Corp | Director | Mar 14, 2016 | D | Indefinite similar: $2,000,000–$19,999,994 | $10,516,500 | 25 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | TESARO, Inc. | Director | Mar 10, 2016 | D | $154,999,915 similar: $1,694,259–$16,000,000 | $154,999,915 | 7 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Vesuvius Pharmaceuticals, Inc. | Director | Jan 5, 2015 | D | $33,000,000 similar: $1,694,259–$16,000,000 | $10,225,258 | 5 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Potenza Therapeutics, Inc. | Director | Dec 5, 2014 | D | $38,000,000 similar: $1,694,259–$16,000,000 | $15,000,000 | 5 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Integrated Diagnostics, Inc. | Director | May 7, 2014 | D | $31,714,889 similar: $500,000–$7,000,000 | $31,714,889 | 6 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Seldar Pharma, Inc. group: Drais | Director | Dec 11, 2013 | D/A | $12,999,000 similar: $1,694,259–$16,000,000 | $12,999,000 | 22 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Centrexion Therapeutics Corp | Director | Dec 3, 2013 | D/A | $35,000,000 similar: $2,000,000–$19,999,994 | $14,728,886 | 98 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Centrexion Therapeutics Corp | Director | Dec 3, 2013 | D | $8,750,000 similar: $2,000,000–$19,999,994 | $8,750,000 | 20 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Centrexion Therapeutics Corp | Director | Nov 22, 2013 | D | $35,000,000 similar: $2,000,000–$19,999,994 | $14,728,886 | 98 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | USDS, Inc. | Director | May 23, 2013 | D | Indefinite similar: $829,831–$9,999,998 | $4,578,466 | 1 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | RADIORX, INC. | Director | Apr 17, 2013 | D/A | Indefinite similar: $2,000,000–$19,999,994 | $20,450,011 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | APPLIED GENETIC TECHNOLOGIES CORP | Director | Nov 29, 2012 | D | $37,530,000 similar: $2,000,000–$19,999,994 | $8,579,358 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ARCION THERAPEUTICS, INC. | Director | Oct 1, 2012 | D | Indefinite similar: $2,000,000–$19,999,994 | $1,500,000 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Seldar Pharma, Inc. group: Drais | Director | Jun 14, 2012 | D | $12,999,000 similar: $1,694,259–$16,000,000 | $5,199,470 | 22 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Telsar Pharma, Inc. group: Drais | Director | May 18, 2012 | D | $14,002,500 similar: $1,694,259–$16,000,000 | $14,002,500 | 26 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | APPLIED GENETIC TECHNOLOGIES CORP | Director | May 3, 2012 | D | $750,000 similar: $2,000,000–$19,999,994 | $750,000 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | RADIORX, INC. | Director | Feb 29, 2012 | D/A | Indefinite similar: $2,000,000–$19,999,994 | $16,490,011 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | TESARO, Inc. | Director | Jun 21, 2011 | D | $101,000,000 similar: $1,694,259–$16,000,000 | $40,000,000 | 17 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | RADIORX, INC. | Director | Feb 28, 2011 | D/A | Indefinite similar: $2,000,000–$19,999,994 | $10,722,011 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | MACROGENICS INC | Director | Jan 31, 2011 | D | $12,016,500 similar: $2,000,000–$19,999,994 | $12,016,500 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ARCION THERAPEUTICS, INC. | Director | Nov 1, 2010 | D | $2,000,000 similar: $2,000,000–$19,999,994 | $400,000 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ARCION THERAPEUTICS, INC. | Director | Apr 22, 2010 | D | Indefinite similar: $2,000,000–$19,999,994 | $1,250,000 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | USDS, Inc. | Director | Apr 5, 2010 | D | Indefinite similar: $829,831–$9,999,998 | $1,530,000 | 2 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Drais Pharmaceuticals Inc group: Drais | Executive Officer | Feb 22, 2010 | D/A | Indefinite similar: $2,000,000–$19,999,994 | $20,000,000 | 31 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ARCION THERAPEUTICS, INC. | Director | Feb 1, 2010 | D | Indefinite similar: $2,000,000–$19,999,994 | $5,000,000 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ANESIVA, INC. | Director | Oct 2, 2009 | D/A | $2,200,000 similar: $2,000,000–$19,999,994 | $2,200,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | APPLIED GENETIC TECHNOLOGIES CORP | Director | Jul 16, 2009 | D/A | $38,799,998 similar: $2,000,000–$19,999,994 | $33,549,998 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ANESIVA, INC. | Director | Jun 2, 2009 | D | $2,000,000 similar: $2,000,000–$19,999,994 | $2,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | ANESIVA, INC. | Director | Feb 2, 2009 | D | $7,000,000 similar: $2,000,000–$19,999,994 | $3,000,000 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); Pharmaceuticals / 506(b) (800 filings); Other / 506(b) (18,678 filings); Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
People and management entities the issuers listed as related persons on the same Form D filings as Arnold L. Oronsky. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Arnold L. Oronsky appears on a new Form D, or when a court case or SEC action is matched to them. See plans →